Ferro-Alloy raises £5.7 million at 25.3% discount to repay Kazakh bonds
Ferro-Alloy has raised £5.7 million at a 25.3% discount, providing funds for bond repayment but creating substantial shareholder dilution.
This article covers information on Ferro-Alloy Resources Limited.
LON:FARWhat has Ferro-Alloy Resources announced?
Ferro-Alloy Resources Limited has raised gross proceeds of £5.7 million by issuing 167,647,046 new ordinary shares.
The shares were issued at 3.4p each, representing a 25.3% discount to the closing mid-market share price on 30 July 2026. That is a sizeable discount, but the financing gives the company enough money to address specified bond liabilities.
Alongside the equity issue, Ferro-Alloy has granted 4 million share options to its intended incoming chief executive, chief financial officer and another senior manager.
The key trade-off for existing investors is straightforward. The balance sheet receives an important injection of cash and the company can repay debt, but shareholders have absorbed substantial dilution at a discounted price.
Investors can read the original company announcement for the complete regulatory disclosure.
Key figures from the fundraising
| Item | Detail |
|---|---|
| Gross proceeds | £5.7 million |
| New shares | 167,647,046 |
| Issue price | 3.4p |
| Discount to previous closing price | 25.3% |
| Shares in issue after admission | 755,398,376 |
| New share options | 4 million |
| Option exercise price | 3.4p |
| Expected admission date | 5 August 2026 |
The new shares will represent approximately 22.2% of Ferro-Alloy's enlarged share capital. Put another way, the share count is increasing by roughly 28.5% compared with the number previously in issue.
That makes this a highly dilutive financing. An existing investor who did not participate will own a smaller percentage of the company once the new shares are admitted.
Why the bond repayment matters
Ferro-Alloy says the £5.7 million gross proceeds are equivalent to US$7.58 million. Combined with US$2 million received under prepayment contracts for future vanadium and molybdenum sales from its existing plant, the company says it has enough money to repay the outstanding principal and accrued interest owed to holders of Tranche 1 and Tranche 3 of its US$20 million Kazakh bond programme.
The precise amount being repaid was not disclosed. The announcement also does not disclose the net proceeds after fundraising costs or how much cash will remain following the repayments.
Even so, replacing bond liabilities with equity can reduce near-term financing pressure because shares do not carry the same contractual repayment obligation as bonds. The cost is transferred to shareholders through dilution rather than future interest and principal payments.
This should therefore be viewed primarily as a balance-sheet transaction, rather than fresh evidence that the underlying Balasausqandiq project has been fully funded.
Ferro-Alloy's wider development plans remain centred on the large vanadium deposit in southern Kazakhstan. Investors looking at the project's economics can revisit the company's previously reported Balasausqandiq feasibility study results.
The 25.3% discount is hard to ignore
Small resource developers often need to balance the urgency of securing cash against the price at which investors are willing to provide it. Here, Ferro-Alloy accepted a 25.3% discount to the previous closing price.
A discount can help ensure that a fundraising is completed, particularly where the company has debt obligations to address. However, the combination of a large number of new shares and a low issue price means the dilution is meaningful.
The announcement does not disclose who subscribed for all of the new shares. It does, however, identify significant participation from directors and Vision Blue Resources, a person closely associated with chairman Sir Mick Davis.
Insiders have put in more money
The related-party subscriptions disclosed in the announcement were:
| Participant | New shares subscribed | Amount invested | Holding after issue |
|---|---|---|---|
| Vision Blue Resources | 65,290,848 | £2,219,889 | 26.15% |
| Nicholas Bridgen | 1,492,702 | £50,752 | 8.52% |
| Christopher Thomas | 2,764,264 | £93,985 | 1.44% |
| Petrus Nienaber | 1,326,846 | £45,113 | 0.33% |
Together, those parties subscribed for 70,874,660 shares and invested approximately £2.41 million based on the disclosed amounts.
Vision Blue Resources remains particularly influential, with a 26.15% holding after admission. The independent directors reviewed the related-party participation and concluded that its terms were fair and reasonable as far as shareholders were concerned.
Insider participation provides some alignment because directors and a major shareholder are committing additional capital on the same 3.4p terms. It does not remove the financing risk or dilution, but it is more encouraging than a raise completed entirely without support from existing insiders.
New options accompany the leadership transition
Ferro-Alloy has also granted 4 million options under its previously approved share option scheme:
- Peter Secker, intended incoming chief executive: 3 million options
- William Callewaert, chief financial officer: 500,000 options
- Andrey Andreyevich Kuznetsov, deputy director general of the operating subsidiary: 500,000 options
The options carry a 3.4p exercise price and become exercisable on 31 July 2029. They can then be exercised for two years.
The options represent approximately 0.53% of the enlarged issued share capital. This is much smaller than the immediate dilution from the fundraising, although it could create further dilution if exercised.
There is also an important qualification around the leadership change. Peter Secker's appointment as incoming chief executive remains subject to his final contract being signed. Current chief executive Nick Bridgen intends to step back from executive responsibilities and support the business as a non-executive director.
Bridgen described the change as succession planning and said it did not reflect reduced confidence in the business. He will retain an 8.52% shareholding after subscribing for further shares.
What Ferro-Alloy shareholders should watch next
The immediate positive is that Ferro-Alloy now says it has sufficient funds to repay the specified bond tranches. That removes a clear near-term use of cash and should simplify part of the company's financing position.
The negatives are equally visible. The raise has been completed at a steep discount, increases the share count substantially and does not disclose how much unrestricted cash will remain after the bond principal and accrued interest are settled.
Investors should now look for confirmation that the bond repayments have been completed, details of the remaining cash position and progress towards finalising Peter Secker's appointment.
Beyond those near-term matters, the central question remains how Ferro-Alloy will fund and execute the Balasausqandiq project's development. The company has previously announced a framework agreement with CC6 for the project, but this announcement does not say that full project financing is in place.
For shareholders, this fundraising buys financial breathing room at a meaningful cost. Attention now turns to whether management can use that improved position to deliver operational and project-financing progress without requiring another heavily discounted equity issue.
Related
Keep reading
Investing
Maruwa annual results: sales rise but profits slip as investment surges
Maruwa delivered higher sales and a stronger order book, but lower profit and heavy investment weighed on annual cash flow.
JoshuaJuly 31, 2026
Investing
Wellnex Life Q4 FY26: Cash Flow Positive Again, but Funding Remains Tight
Wellnex Life ended FY26 with stronger revenue, positive quarterly operating cash flow and $862,000 in cash, but financing remains important.
JoshuaJuly 31, 2026
Investing
AstraZeneca's Datroway wins EU approval in metastatic breast cancer
Datroway's EU approval adds a second breast cancer indication, supported by improved survival and progression-free survival versus chemotherapy.
JoshuaJuly 31, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.